Department of Ultrasound, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou.
Department of Clinical Medicine, Quanzhou Medical College, Quanzhou, China.
Ultrasound Q. 2020 Dec;36(4):375-381. doi: 10.1097/RUQ.0000000000000524.
To estimate the value of gynecologic imaging reporting and data system (GI-RADS) combined with 3-dimensional contrast-enhanced ultrasound (3D-CEUS) scoring system in the differential diagnosis of ovarian tumor. Both of 2-dimensional ultrasound (2D-US) and 3D-CEUS were performed on 114 patients with ovarian masses by Voluson E8 with SonoVue (Bracco, Italy). Besides, dynamic contrast-enhanced-magnetic resonance imaging (DCE-MRI) (Siemens Magneton Verio 3.0T, Germany) was performed on the patients. There were totally 62 benign and 52 malignant ovarian tumors in all patients. The ability of GI-RADS combined with 3D-CEUS scoring system to distinguish benign and malignant ovarian tumors was superior to conventional ultrasound GI-RADS classification. The sensitivity, specificity, and accuracy of GI-RADS combined with 3D-CEUS scoring system were 96.2% and 98.1%, 87.10%, whereas those of MRI were 87.10%, 91.23%, and 92.11% respectively, indicating that there was high concordance in ovarian tumors assessment between the 2 diagnostic methods. The new scoring system has a good correlation with microvessel density (P = 0.000, r = 0.73), estrogen receptor (P = 0.000, r = 0.59), progesterone receptor (P = 0.000, r = 0.56), and matrix metalloproteinase-9 (P = 0.000, r = 0.61). The GI-RADS combined with 3D-CEUS scoring system was valuable in clinical diagnosis and differential diagnosis of ovarian tumor and show good agreement with MRI.
评估妇科影像报告和数据系统（GI-RADS）联合三维对比增强超声（3D-CEUS）评分系统在卵巢肿瘤鉴别诊断中的价值。对 114 例卵巢肿块患者使用 Voluson E8 联合 SonoVue（意大利 Bracco）行二维超声（2D-US）和 3D-CEUS 检查，同时对患者行动态对比增强磁共振成像（DCE-MRI）检查（德国 Siemens Magneton Verio 3.0T）。所有患者中良性肿瘤 62 例，恶性肿瘤 52 例。GI-RADS 联合 3D-CEUS 评分系统鉴别卵巢良恶性肿瘤的能力优于常规超声 GI-RADS 分类。GI-RADS 联合 3D-CEUS 评分系统的灵敏度、特异度和准确度分别为 96.2%和 98.1%、87.10%，而 MRI 的灵敏度、特异度和准确度分别为 87.10%、91.23%和 92.11%，提示两种诊断方法对卵巢肿瘤评估具有高度一致性。新的评分系统与微血管密度（P=0.000，r=0.73）、雌激素受体（P=0.000，r=0.59）、孕激素受体（P=0.000，r=0.56）和基质金属蛋白酶-9（P=0.000，r=0.61）均有良好相关性。GI-RADS 联合 3D-CEUS 评分系统在卵巢肿瘤的临床诊断和鉴别诊断中有价值，与 MRI 有良好的一致性。
